British Journal of Haematology

Papers
(The H4-Index of British Journal of Haematology is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Issue Information122
e‐Posters111
Don't forget cord blood in non‐remission acute myeloid leukaemia!87
Issue Information75
Immunophenotypic clustering in paediatric acute myeloid leukaemia72
Issue Information67
59
Would you like to take some more ruxolitinib after your fedratinib?56
Promises and challenges of artificial intelligence in haematological diagnostics53
Quality of life in childhood immune thrombocytopenia: Revision of the Kids' ITP Tools (KIT)52
Whole‐exome sequencing uncovered genetic diagnosis of severe inherited haemolytic anaemia: Correlation with clinical phenotypes51
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lympho50
Prolonged platelet hyperactivity after COVID‐19 infection48
Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients44
Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant43
Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study42
Population pharmacokinetics of high‐dose methotrexate and 7‐hydroxy methotrexate in Chinese adults with primary central nervous system lymphoma42
Unveiling the responsible antigen in vaccine‐induced immune thrombotic thrombocytopenia41
The oldest case of lymphoma? Insights from a XIII century fresco40
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia40
Management of immunosuppression in post‐transplant lymphoproliferative disorders treated with CAR T cells40
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial40
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross‐sectional survey40
Concomitant HIV‐associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation38
38
Long‐term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium37
Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial37
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation36
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)34
Screening for monoclonal gammopathy of undetermined significance is contraindicated34
A novel PML germline variant as a candidate predisposing genetic aberration in familial acute myeloid leukaemia34
Empagliflozin modulates CD4+ T‐cell differentiation via metabolic reprogramming in immune thrombocytopenia34
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia33
Correction to “Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML 33
0.065469026565552